Clinical Leader Webinar

31. Inspection Readiness For Decentralized Trials 3/31/2025

    Decentralized Clinical Trials (DCTs) enhance research inclusivity by minimizing logistical barriers such as travel, scheduling conflicts, and costs, making participation more accessible.

32. Who's In Charge? How To Ensure Effective Trial Oversight, Leadership 3/19/2025

    Gain valuable insights into the role of sponsor-side Clinical Operations leadership, the risks of over-relying on CROs, and key strategies for fostering collaboration between sponsors and partners.

33. Introducing A Smarter, More Cost-Effective Way To Run Clinical Trials 3/13/2025

    While early-phase trials often rely on less capable, cost-effective systems, the transition to more complex studies in later phases necessitates a more robust EDC system.

34. How To Drive Patient Engagement – The Power Of Concierge Support 3/10/2025

    In this discussion, our panel of experts will explore the critical role of concierge services in clinical trials, focusing on how these services address participant needs.

35. Modernizing Clinical Research With AI And Digital Data 3/7/2025

    Discover how ActiGraph is revolutionizing clinical trials with patient-focused digital data and cutting-edge technology that enhances trial efficiency across all phases.

36. A Biologic Drug's Analytical Journey 3/4/2025

    Gain valuable insights into advanced methods and analysis techniques for high-order structure, physiochemical characterization, cell-based and biochemical assays, and more.

37. A Framework For Selecting Reliable Clinical Endpoints From Real-World DHT Data 2/25/2025

    Dr. Andy Liu presents a case study determining which digital measure of physical activity would be a well-defined and reliable clinical endpoint in a trial including patients with diabetes.

38. Digital Physical Activity Measures In Phase 3 Immunology Trials 2/25/2025

    Dr. Jie Shen, Research Fellow and Director of Digital Science at AbbVie, shares lessons learned from incorporating digital measures of physical activity into Phase 3 immunology clinical trials.

39. Leveraging DHTs To Improve Data Collection And Analysis 2/25/2025

    How can wearable DHTs be leveraged to measure physical activity in patients with immunological diseases, enhancing clinical trials and advancing drug development?

40. Podcast―Nonclinical Considerations When Developing Ophthalmic Drugs 2/20/2025

    Globally recognized consultants discuss how they are addressing the most pressing drug development topics in the ocular field.